Amount of qualified clients: CDEC talked over the uncertainty in the volume of people with reasonably serious to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are classified as owning moderate or ave